[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Zhangzhou Municipal Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":117},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,42,68,93],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":4},"100595664","phase-2-adebrelimab--chemotherapy-as-neoadjuvant-therapy-for-resectable-nsclc-100595664",false,"NCT07035392","Adebrelimab + Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC","A Single-arm, Prospective, Multicenter Clinical Study of Adebrelimab in Combination With Chemotherapy Neoadjuvant Therapy to Resect Non-small Cell Lung Cancer","Inclusion Criteria:\n\n1. 18 years old ≤ age ≤ 70 years old, male or female not limited;\n2. ECOG PS score 0-1 points;\n3. Patients who have not received systematic treatment in the past and agree to undergo radical surgery; Patients without surgical contraindications judged by thoracic surgeons;\n4. Stage II, IIIA, or selective IIIB (T3N2M0 only) squamous or non squamous cell non-small cell lung cancer confirmed by histopathology or cytology and judged by researchers to be capable of undergoing R0 surgical resection for the purpose of cure. Disease staging should be based on the American Joint Committee on Cancer (AJCC)\u002FInternational Union Against Cancer (UICC) NSCLC staging system, 8th edition;\n5. There is sufficient tumor tissue to detect PD-L1 expression level and PD-L1 ≥ 1%;\n6. At least one measurable lesion (according to RECIST 1.1 criteria);\n7. The expected survival period is at least 12 weeks;\n8. Other major organs (liver, kidney, blood system, etc.) are functioning well:\n\n   * Hemoglobin ≥ 90g\u002FL (no blood transfusion, no use of hematopoietic factors, and no medication correction within 2 weeks before the first medication);\n   * Absolute neutrophil count (ANC) ≥ 1.5 × 109\u002FL;\n   * Platelet count ≥ 100 × 109\u002FL; Total bilirubin ≤ 1.5 times the upper limit of normal value;\n   * alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase ≤ 2.5 times the upper limit of normal values;\n   * Serum creatinine ≤ 1.5 times the upper limit of normal value; And the endogenous creatinine clearance rate is ≥ 60ml\u002Fmin; For patients who have not received anticoagulant therapy, the international normalized ratio (INR) of prothrombin time is ≤ 1.5, and the activated partial thromboplastin time (APTT) is ≤ 1.5 times the upper limit of normal.\n9. Expected to be completely resected;\n10. Good lung function can tolerate surgical treatment;\n11. Female participants with fertility must undergo a pregnancy test (serum or urine) within 72 hours before starting the study medication, and the result must be negative. They must also be willing to use a medically recognized and effective contraceptive measure (such as intrauterine device, contraceptive pill, or condom) during the study period and within 90 days after the last administration of the study medication; For male participants whose partners are women of childbearing age, they must agree to use effective methods of contraception or have undergone surgical sterilization during the study period and within 90 days after the last study administration;\n12. The subjects voluntarily joined this clinical study and signed an informed consent form.\n\nExclusion Criteria:\n\n1. Previously received any anti-tumor treatment, including radiotherapy, chemotherapy, immunotherapy, and traditional Chinese medicine anti-tumor treatment (excluding treatment for malignant tumors that have been cured and have no recurrence or metastasis for ≥ 5 years);\n2. Non squamous cell carcinoma histological types of NSCLC with EGFR mutation positive or ALK positive subjects. Non squamous cell carcinoma subjects must undergo EGFR gene testing and ALK gene and\u002For immunohistochemical testing;\n3. Patients with distant metastases (including M1a, M1b, M1c);\n4. Suffering from any active autoimmune disease or history of autoimmune disease (such as uveitis, enteritis, hepatitis, pituitary inflammation, vasculitis, myocarditis, nephritis, hyperthyroidism, hypothyroidism (which can be included after hormone replacement therapy), tuberculosis); Skin diseases that have completely relieved childhood asthma and do not require any intervention or systemic treatment in adulthood (such as vitiligo, psoriasis, or hair loss) can be included, but patients who require medical intervention with bronchodilators cannot be included;\n5. Exclude evidence of past or current pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiological pneumonia, drug-induced pneumonia, imaging confirmed active pneumonia, and severe impairment of lung function;\n6. Subjects who have received systemic therapy with corticosteroids (\\>10 mg\u002Fday of prednisone or other equivalent hormones) or other immunosuppressive agents within 2 weeks prior to their first administration. In the absence of active autoimmune diseases, inhalation or topical use of corticosteroids is allowed, as well as adrenal hormone replacement therapy with a dose of ≤ 10 mg\u002Fday effective dose of prednisone;\n7. Imaging (CT or MRI) shows tumor invasion into large blood vessels or blurred boundaries with blood vessels; Or imaging (CT or MRI) shows the presence of any pulmonary cavities or necrotic lesions, as determined by the researcher;\n8. Individuals who have experienced arterial\u002Fvenous thrombotic events within the first 6 months of enrollment, such as cerebrovascular accidents (including temporary ischemic attacks, cerebral hemorrhage, cerebral infarction), deep vein thrombosis, and pulmonary embolism;\n9. Within the first 3 months of enrollment, there have been significant clinically significant bleeding symptoms or clear bleeding tendencies, such as gastrointestinal bleeding, hemorrhagic gastric ulcers, etc., or they are currently receiving thrombolytic or anticoagulant therapy;\n10. Prior to enrollment, there was a daily hemoptysis volume of 100mL or more or a high risk of hemoptysis determined by the researcher;\n11. Individuals with hypertension who cannot achieve good control with antihypertensive medication (systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg); Grade II or above myocardial ischemia or myocardial infarction, poorly controlled arrhythmia (including QTc interval ≥ 450ms for males and ≥ 470ms for females); According to NYHA standards, patients with grade III-IV cardiac dysfunction or those with left ventricular ejection fraction (LVEF)\\\u003C50% as indicated by cardiac ultrasound examination;\n12. Individuals who have undergone other major surgeries or severe injuries within the two months prior to the start of this experiment;\n13. Urine routine examination indicates urinary protein ≥ (++), or 24-hour urine protein level ≥ 1g, or severe liver and kidney dysfunction;\n14. Uncontrollable pleural effusion, pericardial effusion, or ascites requiring repeated drainage;\n15. Allergic to the experimental drug;\n16. Merge with HIV infection or active viral hepatitis;\n17. Pregnant or lactating women; Subjects with fertility who are unwilling or unable to take effective contraceptive measures;\n18. Individuals with neurological disorders or mental illnesses who are unable to cooperate;\n19. Cervical carcinoma in situ, basal cell or squamous cell carcinoma that can be adequately treated, local prostate cancer after radical surgery, and ductal carcinoma in situ after radical surgery are excluded from concurrent malignant tumors occurring ≤ 5 years before enrollment;\n20. Researchers believe that there are other situations that are not suitable for inclusion.","ALL","18 Years","70 Years",{"count":20,"type":21},32,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This study is a single arm, prospective, multicenter clinical trial, and eligible patients will receive the following treatment regimen: Adebrelimab combined with chemotherapy.The study includes a screening period (from the signing of informed consent by the subjects to no more than 28 days before the first medication, imaging examinations are allowed to be performed within 28 days before the first medication, and tumor tissue biopsy is allowed to be archived within 6 months before the first medication), a treatment period (including neoadjuvant and surgical treatment), and a follow-up period (including safety follow-up and survival follow-up).",[27,28,29],"Adebrelimab (SHR-1316)","NSCLC","Chemotherapy","NOT_YET_RECRUITING","2025-06-24",{"date":33,"type":34},"2025-06-25","ACTUAL",{"date":36,"type":21},"2025-06-20",{"date":38,"type":21},"2026-12-01",{"name":40,"class":41},"Zhangzhou Municipal Hospital","OTHER",{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":67},"100554932","a-study-of-enterorenal-syndrome-assessed-by-gastrointestinal-ultrasound-combined-with-renal-artery-resistance-index-100554932","NCT06505512","A Study of Enterorenal Syndrome Assessed by Gastrointestinal Ultrasound Combined with Renal Artery Resistance Index","A Study on the Significance of Joint Evaluation of Gastrointestinal Ultrasound Results and Renal Artery Resistance Index for Assessing the Intestinal-renal Syndrome in Sepsis Patients","Inclusion Criteria:\n\n* Patients diagnosed with intra-abdominal infections\n* Patients with sepsis or septic shock\n\nExclusion Criteria:\n\n* Patients with open chest or abdominal injury\n* Patients with advanced tumor\n* Patients with uremia\n* Pregnant women","14 Years","85 Years",{"count":52,"type":21},74,"OBSERVATIONAL","In this study, the patients with sepsis caused by abdominal infection were divided into survival group and death group by ultrasound examination of gastrointestinal function, superior mesenteric artery blood flow, and renal artery resistance index. The cross-sectional area of gastric antrum, average time flow rate of superior mesenteric artery, colon diameter, colon peristalsis frequency, and renal artery resistance index of the two groups were compared to determine the progression of entero-renal syndrome as soon as possible. To provide reliable objective basis for clinical decision-making, in order to improve the success rate of rescue.",[56,57],"Sepsis","Urinary Tract Infections","RECRUITING","2025-02-25",{"date":61,"type":34},"2025-02-28",{"date":63,"type":34},"2024-01-19",{"date":65,"type":21},"2025-03-31",{"name":40,"class":41},1,{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":75,"enrollmentInfo":76,"targetDuration":4,"studyType":22,"phases":78,"briefSummary":79,"conditions":80,"keywords":82,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":4},"100552836","phase-2-a-study-of-adebrelimab-combined-with-chemoradiotherapy-in-the-treatment-of-esophageal-small-cell-carcinoma-100552836","NCT06478264","A Study of Adebrelimab Combined With Chemoradiotherapy in the Treatment of Esophageal Small Cell Carcinoma","Efficacy and Safety of Adebrelimab Combined With Chemoradiotherapy in the Treatment of Esophageal Small Cell Carcinoma: a Single-arm, Multicenter, Phase II Clinical Study","Inclusion Criteria:\n\n* 1\\. Sign a written informed consent to join the study voluntarily;\n* 2\\. Histologically or cytologically confirmed patients with small cell carcinoma of the esophagus staging T1N0M0 but unable to tolerate surgery or refusing surgery and patients staging T2-4N0-3M0 \\[according to AJCC 8th edition TNM criteria\\];\n* 3\\. Age 18-75 years old, male or female;\n* 4\\. ECOG PS 0-1;\n* 5\\. No previous systemic treatment for esophageal small cell carcinoma;\n* 6\\. At least one measurable lesion (according to RECIST1.1 criteria);\n* 7\\. Normal functioning of major organs, including:\n\n  1. Blood routine examination (no blood component, cell growth factor, white enhancer, platelet enhancer, anemia correction drugs are allowed within 14 days before the first use of the study drug) :\n\n     White blood cell count ≥4.0×10\\^9\u002FL\n\n     Neutrophil count ≥1.5×10\\^9\u002FL\n\n     Platelet count ≥80×10\\^9\u002FL\n\n     Hemoglobin ≥90 g\u002FL\n  2. Blood biochemical examination:\n\n     Total bilirubin ≤1.5×ULN\n\n     ALT≤2.5 x ULN, AST≤2.5 x ULN,\n\n     Serum creatinine ≤1.5×ULN, or creatinine clearance ≥50mL\u002Fmin (Cocheroft-Gault formula, see Annex 2)\n  3. Coagulation function:\n\nInternational Standardized ratio (INR) ≤1.5×ULN\n\nActivated partial thromboplastin time (APTT) ≤1.5×ULN\n\n* 8\\. Patients must submit pre-treatment tumor tissue samples during the study period;\n* 9\\. Expected survival ≥12 weeks;\n* 10\\. Fertile female subjects are required to take a serum or urine pregnancy test with a negative result within 72 hours before starting the study drug administration, and to use effective contraception (such as an IUD, contraceptive pill or condom) during the trial period and for at least 3 months after the last drug administration; For male subjects whose partners are women of reproductive age, effective contraception should be used during the trial period and within 3 months after the last dose;\n* 11\\. The subjects had good compliance and cooperated with follow-up visits.\n\nExclusion Criteria:\n\n* 1\\. Esophageal perforation or hematemesis;\n* 2\\. Uncontrolled pleural effusion, pericardial effusion or ascites requiring repeated drainage;\n* 3\\. Uncontrolled hypercalcemia or symptomatic hypercalcemia;\n* 4\\. Other malignancies diagnosed within 5 years prior to the first use of the investigational drug, except malignancies with a low risk of metastasis or death (5-year survival \\> 90%), such as adequately treated skin basal cell carcinoma or squamous cell skin cancer or cervical carcinoma in situ, may be considered for inclusion;\n* 5\\. History of any active autoimmune disease or autoimmune disease, including but not limited to: interstitial pneumonia, enteritis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism (may be considered after hormone replacement therapy); Patients with psoriasis or childhood asthma\u002Fallergies in complete remission without any intervention as adults may be considered for inclusion, but patients requiring medical intervention with bronchodilators may not be included;\n* 6\\. Previously received immune checkpoint blocking therapy;\n* 7\\. Subjects who required systemic corticosteroids (\\> 10 mg\u002F day effective dose of prednisone) or other immunosuppressive agents within 14 days prior to initial dosing or during the study period. However, in the absence of active autoimmune disease, subjects were allowed to use topical or inhaled steroids and adrenal hormone replacement therapy at a dose ≤10 mg\u002F day of prednisone effectiveness.\n* 8\\. There are clinical symptoms or diseases of heart that are not well controlled, including but not limited to: (1) NYHA grade II or above heart failure, (2) unstable angina pectoris, (3) myocardial infarction within 1 year, (4) Clinically significant supraventricular or ventricular arrhythmias that are not well controlled without or after clinical intervention;\n* 9\\. Poor nutritional status, BMI \\\u003C 18.5 Kg\u002Fm\\^2; If it is corrected before enrollment after symptomatic nutritional support, it can continue to be considered for enrollment after evaluation by the principal investigator;\n* 10\\. Adverse events greater than grade 2 caused by treatment received before the first use of the investigatory drug that have not recovered (i.e., become grade 1 or reach baseline level), and adverse events (such as neurotoxicity) that are difficult to recover quickly as determined by the investigator can be included;\n* 11\\. History of allergy to any component of adbelimab, etoposide, cisplatin or carboplatin;\n* 12\\. A history of immunodeficiency, including HIV testing positive, or other acquired or congenital immunodeficiency diseases, or a history of organ transplantation or allogeneic bone marrow transplantation;\n* 13\\. Severe infections (CTCAE \\> Grade 2), such as severe pneumonia requiring hospitalization, bacteremia, and infection complications, occurred within 4 weeks prior to the first use of the study drug; Baseline chest imaging indicated active pulmonary inflammation, signs and symptoms of infection within 14 days prior to the first use of the study drug, or the need for oral or intravenous antibiotic treatment, except in cases of prophylactic antibiotic use;\n* 14\\. Patients found to have active pulmonary tuberculosis infection through medical history or CT examination, or had a history of active pulmonary tuberculosis infection within 1 year before enrollment, or had a history of active pulmonary tuberculosis infection more than 1 year ago without formal treatment;\n* 15\\. Hereditary bleeding tendency or blood clotting dysfunction. There were clinically significant bleeding symptoms or definite bleeding tendencies within 3 months prior to enrollment, such as hemorrhagic gastric ulcer, stool occult blood ++ or above at baseline;\n* 16\\. Active hepatitis B (HBV DNA≥2000 IU\u002FmL or 10\\^4 copies\u002FmL), hepatitis C (hepatitis C antibody positive and HCV RNA higher than the lower limit of assay);\n* 17\\. Pregnant or lactating women;\n* 18\\. The investigator determined that there were other factors that might have led to the forced termination of the study, such as other serious medical conditions (including mental illness) requiring co-treatment, alcohol, substance abuse, family or social factors, and factors that might have affected the safety or adherence of the subjects.","75 Years",{"count":77,"type":21},40,[24],"To evaluate the efficacy and safety of adebrelimab combined with chemoradiotherapy in the treatment of esophageal small cell carcinoma",[81],"Esophageal Small Cell Carcinoma",[81,83,84],"Adebrelimab","chemoradiotherapy","2024-06-23",{"date":87,"type":34},"2024-06-27",{"date":89,"type":21},"2024-07-13",{"date":91,"type":21},"2027-07-13",{"name":40,"class":41},{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":4,"eligibilityCriteria":99,"healthyVolunteers":11,"sex":16,"minAge":100,"maxAge":101,"enrollmentInfo":102,"targetDuration":4,"studyType":22,"phases":104,"briefSummary":106,"conditions":107,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":4},"100551304","local-opera-viewing-combined-medical-gymnastics-for-elderly-psci-100551304","NCT06458348","Local Opera Viewing Combined Medical Gymnastics for Elderly PSCI","Construction and Empirical Study of Local Opera Appreciation Combined With Medical Gymnastics Training Program for Elderly Patients With Post-stroke Cognitive Impairment","Inclusion Criteria:\n\nStroke patients who were hospitalized in the Department of Neurology of Zhangzhou Hospital and met the PSCI diagnostic criteria of the Expert Consensus on the Prevention and Treatment of Cognitive Impairment after Stroke in China were the subjects of the study. ① Stroke patients confirmed by neuroimaging, onset time within 1 week; (2) Cognitive impairment occurs after stroke events; ③ The scores of the simple mental state examination scale were points in the illiterate group, points in the primary school group, points in the secondary school group, and points in the college group; ④ can maintain independent sitting position ≥30 min; ⑤ Age ≥60 years old; ⑥ Volunteer to join the study and receive intervention treatment.\n\nExclusion Criteria:\n\n* Other causes affect or lead to cognitive impairment, such as consciousness disorder, malignant tumor, severe liver and kidney insufficiency; ② There are serious cardiopulmonary and other systemic diseases; Visual or hearing impairment; ④ have emotional behavior abnormalities and mental illness (including depression); ⑤ A history of alcohol or drug abuse","60 Years","100 Years",{"count":103,"type":21},160,[105],"NA","local opera viewing combined medical gymnastics for elderly PSCI",[108],"Post-stroke Cognitive Impairment","2024-06-09",{"date":111,"type":34},"2024-06-13",{"date":113,"type":21},"2024-07-01",{"date":115,"type":21},"2026-08-31",{"name":40,"class":41},""]